Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Technical breakout: TENX shares recently passed above their 200-day moving average
• Analyst sentiment is bullish overall: the consensus is a "Moderate Buy" with an average target of $29.67, and recent upgrades include Guggenheim ($34 target) and Cantor Fitzgerald ($35 target).
• Company fundamentals remain early-stage and loss-making: Tenax is a clinical-stage specialty pharma with a $240.94M market cap, reported a quarterly EPS of -$0.38 (beating -$1.26 estimate), analysts forecast -$0.88 EPS for the year, and institutional ownership is low (~1.67%).

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $11.35 and traded as high as $14.92. Tenax Therapeutics shares last traded at $14.01, with a volume of 614,522 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on TENX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. William Blair reissued an "outperform" rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. Guggenheim raised their price target on Tenax Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a report on Monday, March 16th. Cantor Fitzgerald initiated coverage on Tenax Therapeutics in a report on Tuesday, March 17th. They issued an "overweight" rating and a $35.00 price target for the company. Finally, Lifesci Capital raised Tenax Therapeutics to a "strong-buy" rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tenax Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $29.67.

Tenax Therapeutics Stock Down 5.2%

The firm has a fifty day moving average of $13.52 and a 200-day moving average of $11.35. The stock has a market capitalization of $240.94 million, a price-to-earnings ratio of -10.53 and a beta of 1.19.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.88. As a group, research analysts forecast that Tenax Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC raised its holdings in Tenax Therapeutics by 19.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 63,673 shares of the specialty pharmaceutical company's stock worth $776,000 after purchasing an additional 10,245 shares during the last quarter. Letko Brosseau & Associates Inc. acquired a new position in Tenax Therapeutics during the fourth quarter worth $130,000. Virtu Financial LLC acquired a new position in shares of Tenax Therapeutics in the third quarter worth $92,000. Corient Private Wealth LLC acquired a new position in shares of Tenax Therapeutics in the fourth quarter worth $151,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Tenax Therapeutics in the fourth quarter worth $252,000. 1.67% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.